SEC Comment Letter 0000000000-24-011393 to MED-X, INC. (CIK 0001620704)

MED-X, INC. (CIK 0001620704)
Date: Oct. 8, 2024 · CIK: 0001620704 · Accession: 0000000000-24-011393

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 024-12516

Date

October 8, 2024

Author

Not clearly detected

Form

UPLOAD

Company

MED-X, INC. (CIK 0001620704)

Letter

October 8, 2024 Matthew Mills President Med-X, Inc. 8236 Remmet Avenue Canoga Park, CA 91304 Re:Med-X, Inc. Offering Statement on Form 1-A Filed October 3, 2024 File No. 024-12516 Dear Matthew Mills: Our initial review of your offering statement indicates that it fails in material respects to comply with numerous requirements of Regulation A and Form 1-A. More specifically, we note that your filing was made more than nine months after the most recently completed fiscal year end, but it does not include interim financial statements for the six-month period ended June 30, 2024. Also, we note that Management's Discussion and Analysis of Financial Condition and Results of Operation is not included in the filing. We will provide more detailed comments relating to your offering statement following our review of a substantive amendment that addresses these deficiencies. Please contact Joe McCann at 202-551-6262 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Jesse Blue, Esq.

Show Raw Text

October 8, 2024
Matthew Mills
President
Med-X, Inc.
8236 Remmet Avenue
Canoga Park, CA 91304
Re:Med-X, Inc.
Offering Statement on Form 1-A
Filed October 3, 2024
File No. 024-12516
Dear Matthew Mills:
            Our initial review of your offering statement indicates that it fails in material respects
to comply with numerous requirements of Regulation A and Form 1-A. More specifically, we
note that your filing was made more than nine months after the most recently completed
fiscal year end, but it does not include interim financial statements for the six-month period
ended June 30, 2024. Also, we note that Management's Discussion and Analysis of Financial
Condition and Results of Operation is not included in the filing.
            We will provide more detailed comments relating to your offering statement
following our review of a substantive amendment that addresses these deficiencies.
             Please contact Joe McCann at 202-551-6262 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Jesse Blue, Esq.

SecProbe.io